PlainPharmaWatch
CMS PY 2024 Company profile Open Payments data

DECIPHERA PHARMACEUTICALS INC.

DECIPHERA PHARMACEUTICALS INC. reported $21.9M in payments to physicians and teaching hospitals across 4,899 transactions in CMS Open Payments PY 2024.

Pharmaceutical payment transparency data for DECIPHERA PHARMACEUTICALS INC.. Ranked #82 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.

Payment Overview

Total Payments

$21.9M

0.2% of all payments

Transactions

4,899

$4.5K avg

Recipients

3,328

$6.6K avg

Industry Rank

#82

of 1,797 companies

What the Data Shows for DECIPHERA PHARMACEUTICALS INC.

In Program Year 2024, DECIPHERA PHARMACEUTICALS INC. reported $21,897,820.11 in payments to 3,328 physicians and teaching hospitals across 4,899 individual transactions — an average of $4.5K per transaction and $6.6K per recipient. That total places DECIPHERA PHARMACEUTICALS INC. at rank #82 out of 1,797 companies in the CMS Open Payments database, representing 0.2% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for DECIPHERA PHARMACEUTICALS INC. spans 5 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Honoraria" at $282.6K, accounting for 1.3% of the company's reported total and 102 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from DECIPHERA PHARMACEUTICALS INC. received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 3,328 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.

Payment Breakdown by Type

DECIPHERA PHARMACEUTICALS INC. made 5 types of payments. "Honoraria" accounts for 1.3%.

Honoraria $282.6K

1.3% · 102 transactions

Food and Beverage $90.8K

0.4% · 2,918 transactions

Compensation for Services Other Than Consulting $90.3K

0.4% · 44 transactions

Travel and Lodging $71.0K

0.3% · 228 transactions

Consulting Fee $58.3K

0.3% · 36 transactions

Payment Type Amount Transactions
Honoraria $282.6K 102
Food and Beverage $90.8K 2,918
Compensation for Services Other Than Consulting $90.3K 44
Travel and Lodging $71.0K 228
Consulting Fee $58.3K 36

Payment Size Analysis

Average transaction size: $4.5K. Average per recipient: $6.6K.

Total Amount

$21,897,820.11

Avg per Transaction

$4.5K

Avg per Recipient

$6.6K

Payment Transparency Context

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.3B

across 1,797 companies

DECIPHERA PHARMACEUTICALS INC. Share

0.2%

#82 by total payments

Frequently Asked Questions

How much did DECIPHERA PHARMACEUTICALS INC. pay to physicians and hospitals in 2024?
DECIPHERA PHARMACEUTICALS INC. made $21,897,820.11 in payments to physicians and hospitals in Program Year 2024, across 4,899 individual transactions. This represents 0.2% of all industry payments reported to CMS Open Payments.
How many physicians received payments from DECIPHERA PHARMACEUTICALS INC.?
DECIPHERA PHARMACEUTICALS INC. made payments to 3,328 physicians and teaching hospitals in 2024. The average payment per recipient was $6.6K.
What types of payments did DECIPHERA PHARMACEUTICALS INC. make?
DECIPHERA PHARMACEUTICALS INC. made 5 different types of payments. The largest category was "Honoraria" at $282.6K, representing 1.3% of all payments.
How does DECIPHERA PHARMACEUTICALS INC. rank among pharmaceutical companies?
DECIPHERA PHARMACEUTICALS INC. ranks #82 out of 1,797 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from DECIPHERA PHARMACEUTICALS INC.?
The average transaction from DECIPHERA PHARMACEUTICALS INC. was $4.5K in 2024. The company made 4,899 total transactions to 3,328 recipients.
Are the top recipients concentrated for DECIPHERA PHARMACEUTICALS INC.?
The top 5 recipients received $0.00 from DECIPHERA PHARMACEUTICALS INC., representing 0.0% of the company's total payments. Payments are relatively well-distributed across recipients.
Where does the payment data for DECIPHERA PHARMACEUTICALS INC. come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.